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Abstract
Network biomarker as a new type of biomarkers with protein-protein interactions was initiated and investigated
with the integration of knowledge on protein annotations, interaction, and signaling pathway. A number of
methodologies and computational programs have been developed to integrate selected proteins into the
knowledge-based networks via the combination of genomics, proteomics and bioinformatics. Alterations of
network biomarkers can be monitored and evaluated at different stages and time points during the development
of diseases, named dynamic network biomarkers. Dynamic network biomarkers should be furthermore correlated
with clinical informatics, including patient complaints, history, therapies, clinical symptoms and signs, physician’s
examinations, biochemical analyses, imaging profiles, pathologies and other measurements.
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Disease is a disordered or incorrectly functioning cells,
tissue, organ, or system of the body, involved in multiple
proteins, cells, organs and systems with the complexity.
There still remains the poor understanding of molecular
mechanisms by which diseases occur, even though bio-
technologies and knowledge on diseases have been
improved tremendously. Variations of protein-based bio-
markers appear on basis of applications, e.g. functional
neuro-imaging biomarkers can play in detecting, diag-
nosing, assessing treatment response and investigating
neurodegenerative disorders [1], which may why the
emphasis of much recent work has shifted to network-
based biomarkers. The most of preclinical and clinical
studies measure systemic levels of one or a few inflam-
matory proteins as an indicator of pathological altera-
tions or disease severity, while molecular network-based
approaches can describe associations between network
properties, disease biology and capacity to distinguish
between prognostic categories. It was suggested that
information encoded in a network of inflammation pro-
teins could predict clinical outcome after myocardial
infarction [2].
Biomarkers can be gene-, protein-, peptide-, chemical-
or physic-based variables. Of those biomarkers, gene-
and protein-based ones have been focused and explored
mostly from a single gene or protein to multiple genes
or proteins, from the expression to functional indication,
and from the network to dynamic network, in order to
understand a multi-factorial basis responsible for the
pathogenesis of diseases. Protein-protein interactions
play a central and critical role in many biological func-
tions, mediating the signaling pathways. Network bio-
marker as a new type of biomarkers with protein-
protein interactions was initiated and investigated with
the integration of knowledge on protein annotations,
interaction, and signaling pathway. It was found that
network biomarkers discovered on basis of protein
knowledge on the SELDI-TOF-MS data were better
than single biomarkers without any protein-protein
interaction in patient classification [3].
A number of methodologies and computational pro-
grams have been developed to integrate selected pro-
teins into the knowledge-based networks via the
combination of genomics, proteomics and bioinfor-
matics. Those methodologies include gene regulatory
network inference tool (GRNInfer), gene regulatory net-
work reconstruction tool with compound targets
(nGNTInfer), inferring transcriptional regulatory net-
works from high-throughput data (nTRNInfer), inferring
protein-protein interactions by parsimony principle
(nInferPPI), inferring protein-protein interactions based
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network aligner (nMNAligner), detecting drug targets in
metabolic networks by integer linear programming
(nMetaILP), protein structure alignment tool based on
multiple objective optimization (nSamo), annotating
genes with positive samples (nAGPS), parsimonious
tree-grow method for haplotype inference (nPTG), iden-
tifying differentially expressed pathways via a mixed
integer linear programming model (nMILPs), protein-
RNA binding-site prediction (nPRNA), or network
ontology analysis (nNOA). Those have the own advan-
tages and strength on basis of scientific needs and inves-
tigative goals. However, there is still a great need to
validate those according to clinical application, translate
those into the development of disease-specific biomar-
kers, and clarify the exact force of protein-protein
interactions.
Furthermore, alterations of network biomarkers can be
monitored and evaluated at different stages and time
points during the development of diseases, which is
named dynamic network biomarkers. This will provide a
three dimensional imaging of protein-protein interac-
tions to demonstrate the location and time of altered
proteins, interactions or regulations in the network.
Dynamic network biomarkers not only show higher or
lower expression of genes or proteins, but also time-
d e p e n d e n ts t r o n g e ro rw e a k e ri n t e r a c t i o n sb e t w e e n
g e n e so rp r o t e i n s .I th a sc o n s i d e r e da so n eo fp o w e r f u l
ways to detect the bifurcation of gene or protein inter-
actions, indicating the early change of biomarkers and
predicting the occurrence of diseases. One of the most
challenges is to translate biomarkers into clinical appli-
cation and validate the disease specificity. Dynamic net-
work biomarkers have the advantage of demonstrating
pathophysiological changes at different stages and peri-
ods. The disease specificity of dynamic network biomar-
kers was validated by the integration with clinical
informatics which translates clinical descriptive informa-
tion on complaints, sign, symptoms, biochemical ana-
lyses, imaging and therapies into the digital data [4].
Comparing dynamic alterations of network biomarkers
with clinical informatics may allow us to discover dis-
ease-specific, stage-specific, severity-specific or therapy-
sensitive biomarkers.
Clinical bioinformatics has been suggested as a new
emerging science combining clinical informatics, bioin-
formatics, medical informatics, information technology,
mathematics and omics science together [5]. Clinical
bioinformatics was initially proposed to enable
researchers to search online biological databases, use
bioinformatics in the medical practice, select appropri-
ate software to analyze the microarray data for medical
decision-making, and optimize the development of dis-
ease-specific biomarkers and supervise drug target
identification and clinical validation [6]. Understanding
the interaction between clinical informatics and bioin-
f o r m a t i c si st h ef i r s ta n dc r itical step to discover and
develop the new diagnostics and therapies for diseases.
In order to optimally select and validate the disease
specificity and clinical values, dynamic network bio-
markers should be furthermore correlated with clinical
informatics, including patient complaints, history,
therapies, clinical symptoms and signs, physician’s
examinations, biochemical analyses, imaging profiles,
pathologies and other measurements. There is a great
need for scientific channels and tools to bridge clinical
bioinformatics to the development, standardization,
application and optimization of selected dynamic net-
work biomarkers.
There is a real challenge to translate dynamic network
biomarkers into the understanding of clinical symptoms
and signs, disease development and progress, and thera-
peutic strategy. Networks of genes and proteins gener-
ated from computational program on basis of
knowledge present the links and association between,
while such knowledge-integrated interaction is relatively
defined and fixed. However, it is expected that the
strength of interactions between genes or proteins
should be varied during the development of diseases,
rather than only the expression. It is also important to
clarify whether the functional correlation exists between
networks of genes and proteins, network biomarkers dif-
fer from dynamic network biomarkers, there is clinical
relevance and correlation between dynamic network bio-
markers and clinical informatics, or we can understand
molecular mechanism of diseases better from dynamic
network biomarkers. In order to reach clinical applica-
tion, the advantages and disadvantages of protein-based
network biomarkers should be furthermore investigated
to evaluate the potential values of network biomarkers
in the development. Thus, we believe that clinical bioin-
formatics can play an important role in identification
and validation of disease-specific dynamic network
biomarkers.
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